Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belinostat + CHOP
- Development stage
- Phase 1
- Lead developer
- Assertio
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Belinostat + CHOP is a combination chemotherapy regimen consisting of belinostat, a pan-histone deacetylase inhibitor, and the standard CHOP regimen. CHOP comprises cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone. Belinostat exerts antineoplastic activity by inhibiting histone deacetylase enzymes, resulting in altered gene expression and apoptosis in malignant cells. The combination is under investigation as a first-line treatment for peripheral T-cell lymphoma (PTCL), aiming to improve the poor outcomes typically seen with CHOP alone. Clinical studies show that the regimen is generally well-tolerated, with manageable toxicities and a high rate of complete and partial responses in newly diagnosed PTCL patients[1][2][3][4].
- Brand names
- Beleodaq
- Other names
- Bel-CHOP
02
Targets
DNAGR (Glucocorticoid receptor)HDAC (HDAC family)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on belinostat + CHOP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belinostat + CHOP.